journal article·2023-01-16Open access

Characterization and Evaluation of Rapamycin-Loaded Nano-Micelle Ophthalmic Solution

Ting Zhang, Chao Wei, Xianggen Wu, Sai Zhang, Fangnan Duan, Xiaolin Qi, Weiyun Shi, Hua Gao

Abstract

Rapamycin-loaded nano-micelle ophthalmic solution (RAPA-NM) offers a promising application for preventing corneal allograft rejection; however, RAPA-NM has not yet been fully characterized. This study aimed to evaluate the physicochemical properties, biocompatibility, and underlying mechanism of RAPA-NM in inhibiting corneal allograft rejection. An optimized RAPA-NM was successfully prepared using a polyvinyl caprolactam–polyvinyl acetate–polyethylene glycol (PVCL-PVA-PEG) graft copolymer as the excipient at a PVCL-PVA-PEG/RAPA weight ratio of 18:1. This formulation exhibited high encapsulation efficiency (99.25 ± 0.55%), small micelle size (64.42 ± 1.18 nm), uniform size distribution (polydispersity index = 0.076 ± 0.016), and a zeta potential of 1.67 ± 0.93 mV. The storage stability test showed that RAPA-NM could be stored steadily for 12 weeks. RAPA-NM also displayed satisfactory cytocompatibility and high membrane permeability. Moreover, topical administration of RAPA-NM could effectively prevent corneal allograft rejection. Mechanistically, a transcriptomic analysis revealed that several immune- and inflammation-related Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were significantly enriched in the downregulated genes in the RAPA-NM-treated allografts compared with the rejected allogenic corneal grafts. Taken together, these findings highlight the potential of RAPA-NM in treating corneal allograft rejection and other ocular inflammatory diseases.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Corneal Surgery and Treatments · Ocular Surface and Contact Lens · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), Eye Institute of Shandong First Medical University, Jinan 250021, China

State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Eye Institute of Shandong First Medical University, Qingdao 266071, China

School of Ophthalmology, Shandong First Medical University, Jinan 250021, China

College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, China

Funding

National Nature Science Foundation of China · Key R&D Plan of Shandong Province · Taishan Scholars Program · Academic Promotion Program and Innovation Project of Shandong First Medical University

References (54)

Show source-provided references
1. Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients10.1111/j.1600-6143.2012.04269.x ↗
2. Use of sirolimus in pediatric heart transplant patients: A multi-institutional study from the Pediatric Heart Transplant Study Group10.1016/j.healun.2016.09.009 ↗
3. Rapamycin inhibits hepatectomy-induced stimulation of metastatic tumor growth by reduction of angiogenesis, microvascular blood perfusion, and tumor cell proliferation10.1245/s10434-009-0564-8 ↗
4. Kwon, S., Ban, K., Hong, Y.K., Sung, J.S., and Choi, I. (2022). PROX1, a key mediator of the anti-proliferative effect of rapamycin on hepatocellular carcinoma cells. Cells, 11.10.3390/cells11030446 ↗
5. Hyper-synergistic antifungal activity of rapamycin and peptide-like compounds against Candida albicans orthogonally via Tor1 kinase10.1021/acsinfecdis.1c00448 ↗
6. Increased fidelity of protein synthesis extends lifespan10.1016/j.cmet.2021.08.017 ↗
7. Intravenous route to choroidal neovascularization by macrophage-disguised nanocarriers for mTOR modulation10.1016/j.apsb.2021.10.022 ↗
8. Kaarniranta, K., Blasiak, J., Liton, P., Boulton, M., Klionsky, D.J., and Sinha, D. (2022). Autophagy in age-related macular degeneration. Autophagy, 1–13.10.1080/15548627.2022.2069437 ↗
9. Efficacy and safety of intravitreal sirolimus for noninfectious uveitis of the posterior segment: Results from the sirolimus study assessing double-masked uveitis treatment (SAKURA) program10.1016/j.ophtha.2020.03.033 ↗
10. A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema10.1016/j.ophtha.2011.07.034 ↗
11. Rapamycin eye drops suppress lacrimal gland inflammation in a murine model of Sjögren’s syndrome10.1167/iovs.16-19159 ↗
12. Overview of nanoparticulate strategies for solubility enhancement of poorly soluble drugs10.1016/j.lfs.2022.120301 ↗
13. Beltzig, L., Frumkina, A., Schwarzenbach, C., and Kaina, B. (2021). Cytotoxic, genotoxic and senolytic potential of native and micellar curcumin. Nutrients, 13.10.3390/nu13072385 ↗
14. Polymeric micellar co-delivery of resveratrol and curcumin to mitigate in vitro doxorubicin-induced cardiotoxicity10.1002/jps.24042 ↗
15. Yusuf, O., Ali, R., Alomrani, A.H., Alshamsan, A., Alshememry, A.K., Almalik, A.M., Lavasanifar, A., and Binkhathlan, Z. (2021). Design and development of D-α-tocopheryl polyethylene glycol succinate-block-poly(ε-caprolactone) (TPGS-b-PCL) nanocarriers for solubilization and controlled release of paclitaxel. Molecules, 26.10.3390/molecules26092690 ↗
16. Ocular drug delivery to the anterior segment using nanocarriers: A mucoadhesive/mucopenetrative perspective10.1016/j.jconrel.2021.06.011 ↗
17. Biopolymer-based nanoparticles with tunable mucoadhesivity efficiently deliver therapeutics across the corneal barrier10.1016/j.msec.2021.111890 ↗
18. Cyclosporine-loaded micelles for ocular delivery: Investigating the penetration mechanisms10.1016/j.jconrel.2022.07.019 ↗
19. Rapamycin nano-micelle ophthalmic solution reduces corneal allograft rejection by potentiating myeloid-derived suppressor cells’ function10.3389/fimmu.2018.02283 ↗
20. Enhanced autophagy alleviated corneal allograft rejection via inhibiting NLRP3 inflammasome activity10.1111/ajt.16968 ↗
21. Polysorbate 80 coated poly (ε-caprolactone)-poly (ethylene glycol)-poly (e-caprolactone) micelles for paclitaxel delivery10.1016/j.ijpharm.2012.05.015 ↗
22. Preformulation studies of a liposomal formulation containing sirolimus for the treatment of dry eye disease10.1089/jop.2015.0032 ↗
23. New micelle myricetin formulation for ocular delivery: Improved stability, solubility, and ocular anti-inflammatory treatment10.1080/10717544.2019.1622608 ↗
24. New nanomicelle curcumin formulation for ocular delivery: Improved stability, solubility, and ocular anti-inflammatory treatment10.1080/03639045.2017.1349787 ↗
25. Development and effects of tacrolimus-loaded nanoparticles on the inhibition of corneal allograft rejection10.1080/10717544.2019.1582728 ↗
26. Ultra-small micelles based on polyoxyl 15 hydroxystearate for ocular delivery of myricetin: Optimization, in vitro, and in vivo evaluation10.1080/10717544.2019.1568624 ↗
27. Formulation of olopatadine hydrochloride viscous eye drops—Physicochemical, biopharmaceutical and efficacy assessment using in vitro and in vivo approaches10.1016/j.ejps.2021.105906 ↗
28. Drug permeability profiling using cell-free permeation tools: Overview and applications10.1016/j.ejps.2018.04.016 ↗
29. Permeability of glibenclamide through a PAMPA membrane: The effect of co-amorphization10.1016/j.ejpb.2018.06.007 ↗
30. Simon, A., Nghiem, K.S., Gampe, N., Garádi, Z., Boldizsár, I., Backlund, A., Darcsi, A., Nedves, A.N., and Riethmüller, E. (2022). Stability study of Alpinia galanga constituents and investigation of their membrane permeability by ChemGPS-NP and the parallel artificial membrane permeability assay. Pharmaceutics, 14.10.3390/pharmaceutics14091967 ↗
31. Establishment of a murine model of chronic corneal allograft dysfunction10.1007/s00417-010-1403-0 ↗
32. Adoptive transfer of donor corneal antigen-specific regulatory T cells can prolong mice corneal grafts survival10.1097/ICO.0b013e3181ea4999 ↗
33. JMJD3 facilitates C/EBPbeta-centered transcriptional program to exert oncorepressor activity in AML10.1038/s41467-018-05548-z ↗
34. Rapamycin-cyclodextrin complexation: Improved solubility and dissolution rate10.1007/s10847-010-9885-2 ↗
35. A grafted copolymer-based nanomicelles for topical ocular delivery of everolimus: Formulation, characterization, ex-vivo permeation, in-vitro ocular toxicity, and stability study10.1016/j.ejps.2021.105735 ↗
36. Linolenic acid-modified PEG-PCL micelles for curcumin delivery10.1016/j.ijpharm.2014.05.059 ↗
37. Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk10.1016/j.ajo.2010.03.010 ↗
38. Pretreatment of rapamycin before allogenic corneal transplant promotes graft survival through increasing CD4 (+) CD25 (+) Foxp3 (+) regulatory T cells10.6002/ect.2012.0025 ↗
39. Influence of combined treatment of low dose rapamycin and cyclosporin A on corneal allograft survival10.1007/s00417-010-1420-z ↗
40. In vitro and in vivo performance of a dual drug-eluting stent (DDES)10.1016/j.biomaterials.2010.01.147 ↗
41. Development of quercetin-loaded PVCL-PVA-PEG micelles and application in inhibiting tumor angiogenesis through the PI3K/Akt/VEGF pathway10.1016/j.taap.2022.115889 ↗
42. Koutsoviti, M., Siamidi, A., Pavlou, P., and Vlachou, M. (2021). Recent advances in the excipients used for modified ocular drug delivery. Materials, 14.10.3390/ma14154290 ↗
43. Rheological characterization of polyvinyl caprolactampolyvinyl acetate-polyethylene glycol graft copolymer (Soluplus®) water dispersions10.1007/s00396-013-3077-8 ↗
44. Soluplus micelles for improving the oral bioavailability of scopoletin and their hypouricemic effect in vivo10.1038/aps.2016.126 ↗
45. Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo10.1016/j.ejps.2011.11.025 ↗
46. Improved anticancer activity of betulinic acid on breast cancer through a grafted copolymer-based micelles system10.1080/10717544.2021.1979125 ↗
47. Influence of sirolimus-loaded nanoparticles on physiological functions of native human polymorphonuclear neutrophils10.1016/j.nano.2012.01.011 ↗
48. Local delivery of sirolimus nanoparticles for the treatment of in-stent restenosis10.1002/ccd.24331 ↗
49. Exploring the intrinsic micro-/nanoparticle size on their in vivo fate after lung delivery10.1016/j.jconrel.2022.05.006 ↗
50. The topical ocular delivery of rapamycin to posterior eye tissues and the suppression of retinal inflammatory disease10.1016/j.ijpharm.2022.121755 ↗
51. Improvement in the water solubility of drugs with a solid dispersion system by spray drying and hot-melt extrusion with using the amphiphilic polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer and d-mannitol10.1016/j.ejps.2017.09.014 ↗
52. Gao, H., Huang, T., Pan, Z., Wu, J., Xu, J., Hong, J., Chen, W., Wu, H., Kang, Q., and Zhu, L. (2020). Survey report on keratoplasty in China: A 5-year review from 2014 to 2018. PLoS ONE, 15.10.1371/journal.pone.0239939 ↗
53. The NLRP3 inflammasome regulates corneal allograft rejection through enhanced phosphorylation of STAT310.1111/ajt.16071 ↗
54. Blockage of P2X7R suppresses Th1/Th17-mediated immune responses and corneal allograft rejection via inhibiting NLRP3 inflammasome activation10.1016/j.exer.2021.108792 ↗